Celyad Oncology SA (EBR:CYAD)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.5480
+0.0040 (0.74%)
Mar 28, 2025, 5:25 PM CET
54.37%
Market Cap 22.70M
Revenue (ttm) 72.00K
Net Income (ttm) -7.75M
Shares Out 41.43M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,187
Average Volume 56,855
Open 0.5210
Previous Close 0.5440
Day's Range 0.5210 - 0.5690
52-Week Range 0.2120 - 1.2200
Beta 1.21
RSI 50.21
Earnings Date Apr 4, 2025

About Celyad Oncology

Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement wi... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 19
Stock Exchange Euronext Brussels
Ticker Symbol CYAD
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.